Patent classifications
C12N2770/32652
RECOMBINANT ENTEROVIRUSES AND USES THEREOF
The present disclosure generally relates to, inter alia, to nucleic acid constructs encoding a modified enterovirus genome that is devoid of partial or complete nucleic acid sequences encoding viral structural proteins. The disclosure also provides compositions and methods useful for producing defective interfering particles (DIPs) of enteroviruses, and for the prevention and/or treatment of various health conditions such as immune diseases and viral infections.
Engineered cells with decreased gene expression resulting in increased viral production
Disclosed are compositions and methods for increasing virus production. In particular, disclosed herein are cell or cell line comprises reduced expression of one or more cellular genes selected from the group comprising COQ9, FGF2, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, STRADA, SVOPL, and/or ZFYVE9 for use in increasing viral production.
A PROCESS FOR ENTEROVIRUS PURIFICATION AND INACTIVATION AND VACCINE COMPOSITIONS OBTAINED THEREOF
The present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations of various enteroviruses so obtained.
METHODS AND COMPOSITIONS RELATED TO INCREASED VIRAL PRODUCTION
Disclosed are compositions and methods for increasing virus production.
Process for enterovirus purification and inactivation and vaccine compositions obtained thereof
The present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations of various enteroviruses so obtained.